Another RICOdiculous Decision
Drug & Device Law
JULY 24, 2023
See , e.g. , In re Thalomid & Revlimid Antitrust Litigation , 2018 WL 6573118, at *4 (D.N.J. 30, 2018); In re Skelaxin (Metaxalone) Antitrust Litigation , 299 F.R.D. It is not clear that [defendants] will − or even can − avail themselves of a TPP-by-TPP causation defense using doctor-by-doctor testimony. 555, 565 (E.D.
Let's personalize your content